Index

Note: Page numbers of article titles are in **boldface** type.

A

Adaptive immunity, description of, 584–585
Adjuvants, 587
Adolescents, vaccines for, 603–604
Adoptees, international, medical issues of, 639, 641
Adult vaccination, **611–632**
  improving coverage for, 613
  recommendations for, 614–630
  schedules for, 611–613
Advisory Committee on Immunization Practices
  TdaP vaccination recombinations of, 615–616
  web site of, 751
Age considerations, in immune response, 590
Agglutination test, for antibody measurement, 588
Allegheny County Immunization Coalition, 758–759
American Academy of Family Practice
  conference of, 758
  web site of, 753
American Academy of Pediatrics
  conference of, 758
  web site of, 753
American College of Physicians, conference of, 758
American Recovery and Reinvestment Act of 2009, 749
Anthrax, vaccines for, 732
Antibodies
  measurement of, 587–590
  production of, 585
Autism, fear of, vaccine refusal and, 718
Autoimmune disease, adjuvants and, 587

B

B cells, function of, 585
BCG vaccine, for tuberculosis, 635, 732
Bordetella pertussis infections. *See* Pertussis.
Botulism, immune globulin for, 686

C

Cancer vaccines
  for prevention, 703–712
    hepatitis B, 703–704
    human papillomavirus, 704–712

Prim Care Clin Office Pract 38 (2011) 777–786
doi:10.1016/S0095-4543(11)00083-2
primarycare.theclinics.com
0095-4543/11/$ – see front matter

© 2011 Elsevier Inc. All rights reserved.

Cancer (*continued*)
for treatment, 712–713
Catch-up schedule, for pediatric vaccination, 596–597
Centers for Disease Control, information from, 759
travel medicine, 645
vaccination regulations, 638–641
web sites, 750–751
Chemoprophylaxis, for malaria, 672
Chemotherapy, cancer vaccines with, 712–713
Chickenpox. *See* Varicella-zoster virus infections.
Children's Hospital of Philadelphia, Vaccine Education Center, 755
Cholera vaccine, for travelers, 648
Clostridium botulinum toxin, immune globulin for, 686
Clostridium tetani toxins. *See* Tetanus.
Comprehensive Clinic Assessment Software Application, 751
Conferences, vaccine information at, 757–758
Conjugate vaccines
Haemophilus influenzae, 599–600
meningococcal, 603, 618–619
pneumococcal, 600–601
Corynebacterium diphtheriae infections. *See* Diphtheria.
Cytomegalovirus, immune globulin for, 685–686

D

Dengue prevention, for travelers, 673–675
Diarrhea, traveler's, 675–676
Diphtheria, 614
vaccines for, 603. *See also* DT (diphtheria, tetanus) vaccine *and others.*
Directory of Immunization Coalitions, 758–759
DT (diphtheria, tetanus)
administration of, 733
available products, 733
for immigrants, 640
DTaP (diphtheria, tetanus, pertussis) vaccine, 601, 615, 640
DTP (diphtheria, tetanus, pertussis) vaccine, for immigrants, 640
Dt Td vaccine, contraindications to, 624

E

Electronic health records, 748–749
Enzyme-linked immunosorbent assay
for antibody measurement, 588
for tuberculosis, 635
Enzyme-linked immunospot test, for tuberculosis, 635
Expert opinion, on vaccines, 759

F

Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) trial, 767–768
Food and Drug Administration, web site of, 756
Foreign-born populations, vaccine-preventable diseases in, **633–642**
burden of, 634–638
health care access problems and, 634

international adoptees, 639, 641
refugees, 638–640
risk assessment in, 634
statistics on, 633–634
travel effects on, 638
FUTURE (Females United to Unilaterally Reduce Endo/Ectocervical Disease) trial, 767–768

G

Google, information sources on, 755–756
Group on Immunization Education, 758

H

Haemophilus influenzae infections, vaccines for, 599–600
administration of, 733–735
available products, 733–735
contraindications to, 605
for immigrants, 640
Health Information Technology for Economic and Clinical Health Act, 749
Hepatitis A, 620
immune globulin for, 655
in foreign-born population, 637
vaccines for, 603, 620–621
administration of, 735
available products, 735
contraindications to, 605, 625
for immigrants, 640
for travelers, 649–651
Hepatitis B, 621
immune globulin for, 682–693
in foreign-born population, 637–638
screening for, 768–771
vaccines for, 599, 621–622
administration of, 736
available products, 736
contraindications to, 605, 625
for immigrants, 640
for premature infants, 604
for travelers, 652–655
in cancer prevention, 703–704
indications for, 768–770
response to, 768–770
Hepatocellular carcinoma, prevention of, hepatitis B vaccine for, 703–704
Herpes zoster, 622–623
vaccines for, 623
administration of, 744
available products for, 744
contraindications to, 625
safety of, 768
Human papillomavirus infections, 619, 704–712
acquisition of, 705–707
cancer development in, 707–708

Human (*continued*)
epidemiology of, 704–705
in foreign-born population, 638
pathogenesis of, 707
vaccines for, 619–620
administration of, 737
available products, 737
contraindications to, 626
for cancer prevention, 708–712
for pediatric patients, 603–604
for women already infected, 767–768

I

Immigrant(s). *See* Foreign-born populations.
Immigration and Nationality Act, vaccination requirements of, 639
Immune globulin. *See* Passive immunization.
Immune response, to vaccines, **581–593**
improving efficacy of, 586–587
overview of, 583–586
quantifying of, 587–590
Immunization. *See* Vaccines and vaccination.
Immunization Action Coalition, 751–752
Immunofluorescence test, for antibody measurement, 588
Infectious Diseases Society of America, Seasonal and Pandemic Influenza Conference of, 757
Influenza, 623
H1N1 2009 pandemic of, **693–701**
antiviral therapy for, 696–698
diagnosis of, 695–696
risk factors for, 695
spread of, 693–695
versus past pandemics, 693
vaccines for, 623, 627–628
administration of, 737–738
available products, 737–738
contraindications to, 626
for immigrants, 640
hesitation to receive, 770, 772–773
H1N1, 698–699
refusal of, 725–726
Information sources, for vaccines and vaccination, **747–761**
camaraderie groups, 758–759
conferences, 757–758
electronic health records, 748–749
expert opinion, 759
favorite, 759–760
for travelers, 645
journals, 759
newsletters, 756–757
registries, 748–749
schedules, 731

textbooks, 759
web sites, 750–756
Innate immunity, description of, 583
Institute for Vaccine Safety, web site of, 755
Institute of Medicine, web site of, 756
International Certificates of Vaccination, 647
IPV (inactivated polio vaccine), 601, 734
administration of, 740
available products for, 740
contraindications to, 605
for immigrants, 640
for travelers, 668–669

J

Japanese encephalitis vaccine, 655–657, 738
John Hopkins Antibiotic Guide, 756
John Hopkins University School of Public Health, web site of, 755
Journals, vaccine information in, 759

M

Malaria prevention, for travelers, 671–673
Measles, 628
vaccines for. *See* MMR (measles, mumps, rubella) vaccines.
Medscape web site, 755
Memory, immunologic, 585–586
Meningococcal infections, 618–619
vaccines for, 603
administration of, 739
available products for, 739
contraindications to, 605, 626
for immigrants, 640
for travelers, 657–660, 671
MMR (measles, mumps, rubella) vaccines, 602
administration of, 738–739
available products for, 738–739
contraindications to, 606, 625
for immigrants, 640
risks and benefits of, 765–766
MMRV (measles, mumps, rubella, varicella) vaccines, risks and benefits of, 765–766
Monoclonal antibodies, for infections, 686–688
Morbidity and Mortality Weekly Report, 756
Motaviumab, for respiratory syncytial virus prevention, 688
Mumps, 628–629
vaccines for. *See* MMR (measles, mumps, rubella) vaccines.

N

National Childhood Vaccine Injury Act, 598–599
National Foundation for Infectious Diseases
Annual Conference on Vaccine Research, 757
web site of, 755
National Immunization Conference, 757

National Network for Immunization Information, 754
National Vaccine Advisory Committee, 599, 755
National Vaccine Injury Compensation Program, 730–731
National Vaccine Program Office, web site of, 755
Needles, for vaccination, 731
Neisseria meningitidis infections. *See* Meningococcal infections.
Newsletters, for vaccine information, 756

O

Office immunization, **729–745**
  factors affecting, 729–731
  opposition forces against, 729–730
  vaccines for
    administration of, 731–732
    available products, 732–744
OPV (oral polio vaccine), 601, 640
Oseltamivir, for influenza, 696–697

P

Palivizumab, for respiratory syncytial virus prevention, 606–607, 687–688
Papillomavirus infections. *See* Human papillomavirus infections.
Passive immunization, **681–691**
  for botulism, 686
  for cytomegalovirus, 685–686
  for hepatitis B, 682–683
  for rabies, 684–685
  for respiratory syncytial virus, 687–688
  for tetanus, 685
  for varicella, 683–684
  indications for, 681
  products for, 681–682
Pediatric patients, vaccination for, **595–609**
  adolescent, 603–604
  contraindications to, 604–605
  coverage rates in, 596, 598
  for premature infants, 604, 606–607
  immune response in, 590
  interchangeability of, 598
  principles of, 595–599
  routine childhood, 599–603
  safety of, 598–599
  schedules for, 595–597
Pertussis, 614
  vaccines for, 601, 603. *See also* DTaP (diphtheria, tetanus, pertussis) vaccine; TdaP (tetanus, diphtheria, pertussis) vaccine.
Plague, vaccine for, for travelers, 660
Plasmodium infections, prevention of, 671–673
Pneumococcal infections, vaccines for, 600–601
  administration of, 740
  available products for, 740
  contraindications to, 605, 624

for adults, 616, 618
for immigrants, 640
Poliovirus, vaccines for, 601, 734
administration of, 740
available products for, 740
contraindications to, 605
for immigrants, 640
for travelers, 668–669
Pregnancy, vaccination during, 764–765
Premature infants, vaccines for, 604, 606–607
Public health, vaccine coverage and, 719–720
Publications, vaccine information in, 759

R

Rabies virus
immune globulin for, 684–685
vaccines for
administration of, 741
available products for, 741
for travelers, 647, 661–662
Radioimmunoassay test, for antibody measurement, 588
Refugees, medical issues of, 638–650
Refusal of vaccination, **717–728**
addressing confusion about, 720
by health care workers, 725–726
causes of, 717–719
due to simultaneous administration, 718
history of, 729–730
individual decision making and, 719–720
influenza, 770, 772–773
physician response to, 723–725, 751
public health impact of, 719–720
total, 722–723
versus alternative schedules, 721–722
Registries, immunization, 748–749
Respiratory syncytial virus, prevention of, 606–607, 687–688
Rotavirus, vaccines for, 601–602
administration of, 741
available products for, 741
contraindications to, 606
for immigrants, 640
for premature infants, 604
Rubella, 629–630
vaccines for, 629–630. *See also* MMR (measles, mumps, rubella) vaccines.

S

Safety, of vaccines, 598–599, 698–699, 730–731
Seasonal and Pandemic Influenza Conference of, 757
Shingles. *See* Herpes zoster.
Shingles Prevention Study, 768
Shots by STFM, 758

ShotsOnline, 752–753
Smallpox vaccination
  available products for, 742
  for travelers, 670
Society of Teachers of Family Medicine Group on Immunization Education
  conference of, 758
  web site of, 752–753
Streptococcus pneumoniae infections. *See* Pneumococcal infections.
Stress, immune response and, 590

T

T cells, activation of, 584–585
Td (tetanus, diphtheria) vaccine, 640, 733
TdaP (tetanus, diphtheria, pertussis) vaccine, 603, 615
  administration of, 733–735
  available products, 733–735
  contraindications to, 605, 624
Tetanus, 615–616
  immune globulin for, 685
  vaccines for, 601, 603. *See also* DtaP (diphtheria, tetanus, pertussis) vaccine; TdaP (tetanus, diphtheria, pertussis) vaccine.
Textbooks, vaccine information in, 759
Tickborne encephalitis, vaccines for, 663–665
T-Lymphocyte Proliferation assay, 589–590
Travel medicine, **643–679**
  as medical specialty, 644–645
  dengue prevention in, 673–675
  emerging infections in, 644
  for foreign-born population, 638
  information on, 645
  malaria prevention in, 671–673
  practice of, 645
  pretravel consultation in, 645–646
  traveler's diarrhea management in, 675–676
  vaccinations before, 646–671
Tropical medicine. *See* Travel medicine.
Tuberculosis
  blood tests for, 635
  in foreign-born population, 634–636
  vaccine for, 635, 732
Typhoid, vaccines for
  administration of, 742
  available products for, 742
  for travelers, 665–667

U

United Nations Convention Relating to the Status of Refugees, 638–639

V

Vaccine Adverse Event Reporting System, 598–599, 730, 756
Vaccine information statements, 750–751

Vaccines and vaccination
administration of
in office setting, 731–744
outside United States, 639, 641
adverse events associated with, 763–764
classification of, 582
contraindications to, 763–764
coverage rates in, 596, 598
dose number for, 589
efficacy of, 589–590
equipment for, 731
for adults, **611–632**
for cancer, **703–715**
for foreign-born populations, **633–642**
for passive immunization, **681–691**
for pediatric patients, **595–609**
forces opposing, 729–730
immune response to, **581–593**
in influenza H1N1 pandemic, **693–701**
in office setting, **729–745**
in travel medicine, **643–679**
inactivated, 582
information sources for. *See* Information sources.
interchangeability of, 598
mechanism of action of, 582
new, advice on, 748
patient questions about, **763–776**
refusal of. *See* Refusal of vaccination.
safety of, 598–599, 698–699, 730–731
schedules for
alternative, 721–722
in adults, 611–613
in pediatric patients, 595–597
information sources for, 731, 748
subtypes of, 582
Vaccines for Children Program, 613, 730
Varicella-zoster virus infections, 622
breakthrough disease in, 766–767
immune globulin for, 683–684
vaccines for, 602, 622
administration of, 743
available products for, 743
cell proliferation assay for, 589–590
contraindications to, 605, 625
for immigrants, 640

W

Web sites, for vaccine information, 750–756
Whooping cough. *See* Pertussis.
Wilderness Medicine Society, 646

Y

Yellow fever, vaccines for, 667–668, 671
  administration of, 743
  available products for, 743

Z

Zanamivir, for influenza, 696–697
Zoster. *See* Herpes zoster.